Horizon Discovery Inks Service Agreement with GSK | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has signed a commercial service agreement with GlaxoSmithKline in the area of cancer metabolomics.

Under the agreement, Cambridge, UK-based Horizon will use its X-MAN cell lines to provide GSK with services including the characterization of biomarkers, disease signatures, and therapeutic targets.

Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.